President Donald Trump has directed the Food and Drug Administration (FDA) to ramp up its efforts to ensure that advertising of prescription drugs directed to consumers is transparent and accurate.
That includes requiring drug makers to provide more information on the risks of using the drug, and stepping up enforcement of federal laws regulating these ads.
This action, ordered by a presidential memorandum on Sept. 9, could have far-reaching implications for drug manufacturers, who collectively spend billions each year to present their products directly to prospective patients through broadcast media.
The ripple effect could impact new media, as the FDA ramps up enforcement in digital spaces, including via social media influencers, algorithmically served ads, artificial intelligence (AI), and chatbots….
Trump’s Crackdown on Prescription Drug Ads: What to Know
